Report
Novartis : Q2: Good figures, in line with our forecasts. The group should sell the US generics business.
>Q2 2018: sales +5% cc/ core EBIT +7% cc/ core EPS +4% cc – In line with our estimates - Novartis reported its Q2 results this morning: good figures in line with our expectations. Group sales came to $ 13.2bn (+5% cc / +7.5% reported), in line with our expectations and 1.5% higher than the consensus. Pharma performed well (+8% cc) due in particular to good resilience in Glivec sales in the face of competition from generics but also thanks to “new†products (Cosentyx a...
Underlying
NOVARTIS N 2. LINIE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oussema Denguir
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.